SPRUSON&FERGUSON

Australia

Patents Act 1990

Notice Of Entitlement

I, John David O'Connor, of 31 Market Street, Sydney, New South Wales, 2000, Australia, Patent Attorney for the Applicant/Nominated Person in respect of Application No. 10449/95, state the following:-

The Applicant/Nominated Person has entitlement from the actual inventors as follows:

The Applicant/Nominated Person is the assignee of the actual inventors.

The Applicant/Nominated Person is entitled to rely on the application listed in the Declaration under Article 8 of the PCT as follows:

The Applicant/Nominated Person is the assignee of the basic applicants.

The basic application listed on the Declaration under Article 8 of the PCT is the first application made in a Convention country in respect of the invention.

DATED 18 April 1996

John David O'Connor

AU9510449

(12) PATENT ABRIDGMENT (11) Document No. AU-B-10449/95
(19) AUSTRALIAN PATENT OFFICE (10) Acceptance No. 699630

(54) Title
NOVEL A1 ADENOSINE RECEPTOR AGONISTS AND ANTIAGONISTS

International Patent Classification(s)
(51)[6] C07D 473/08 A61K 031/52 C07D 519/00 C07H 019/167

(21) Application No. : 10449/95 (22) Application Date : 28.10.94

(87) PCT Publication Number : WO95/11904

(30) Priority Data

(31) Number (32) Date (33) Country
08/144459 28.10.93 US UNITED STATES OF AMERICA

(43) Publication Date : 22.05.95

(44) Publication Date of Accepted Application : 10.12.98

(71) Applicant(s)
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

(72) Inventor(s)
LUIZ BELARDINELLI; RAY OLSSON; STEPHEN BAKER; PETER J SCAMMELLS; PETER GERARD MILNER; JURG ROLAND PFISTER; GEORGE FREDERIC SCHREINER

(74) Attorney or Agent
SPRUSON & FERGUSON , GPO BOX 3898, SYDNEY NSW 2001

(56) Prior Art Documents
AU 51384/93

(57) Claim

1. A compound which binds to an adenosine receptor, wherein said compound is an epoxide of xanthine, adenosine, or an analog, derivative, isomer, or salt thereof.

2. The compound, according to claim 1, wherein said xanthine epoxide is an epoxide of 1,3-dialkylxanthine.

3. The compound, according to claim 2, wherein said 1,3-dipropylxanthine is selected from the group consisting of 1,3-dipropyl-8-oxiranyl xanthine, 1,3-dipropyl-8-epoxyalkylxanthine; 1,3-dipropyl-8-epoxybicycloalkylxanthine; 1,3-dipropyl-8-{3-oxatricyclo[3.2.1.$0^{2,4}$]oct-6(7)yl} xanthine; and 1,3-dipropyl-8-{7-oxabicyclo[2.2.1]hept-2-en-5(6)yl} xanthine.

.../2

4. The compound according to claim 1, wherein said compound has the structure:



wherein R_1 and R_2 are the same or different, and can be H or an alkyl group of 1-4 carbons, and n = 0-4.

5. The compound, according to claim 1, wherein said compound has the structure:



wherein R_1 and R_2 are the same or different, and can be H or an alkyl group of 1-4 carbons, R_3 is either O or $(CH_2)_{1-4}$, and n = 0-4.

10. A method for modulating the biological activity of adenosine, said method comprising administering an effective amount of a compound, wherein said compound is an epoxide of xanthine, adenosine, or an analog, derivative, isomer, or salt thereof.

15. The method, according to claim 10, wherein said biological activity of adenosine is modulated for treatment of a patient having a cardiac, renal, hepatic, or pulmonary disease.

16. The method, according to claim 13, wherein the biological activity of adenosine is modulated to produce diuresis.

17. The method, according to claim 13, wherein the biological activity of adenosine is modulated to produce bronchodilation.

18. The method, according to claim 13, wherein, when adenosine is exogenously administered, the biological activity of adenosine is modulated to counteract a side effect of said administered adenosine.

OPI DATE 22/05/95 APPLN. ID 10449/95
AOJP DATE 06/07/95 PCT NUMBER PCT/US94/12388
AU9510449

IN

(51) International Patent Classification 6 :
C07D 473/08, C07H 19/167, C07D 519/00, A61K 31/52 // (C07D 519/00, 493:00, 473:00)

A1

(11) International Publication Number: WO 95/11904

(43) International Publication Date: 4 May 1995 (04.05.95)

(21) International Application Number: PCT/US94/12388

(22) International Filing Date: 28 October 1994 (28.10.94)

(30) Priority Data:
08/144,459 28 October 1993 (28.10.93) US

~~(71) Applicant: UNIVERSITY OF FLORIDA [US/US]; 186 Grinter Hall, Gainesville, FL 32611 (US).~~

(72) Inventors: BELARDINELLI, Luiz; 4332 N.W. 9th Place, Gainesville, FL 32605 (US). OLSSON, Ray; 5114 W. Cleveland Street, Tampa, FL 33609-3504 (US). BAKER, Stephen; 2210 N.W. 20th Terrace, Gainesville, FL 32607 (US). SCAMMELLS, Peter, J.; Unit 3/69, Fryers Road, Highton, VIC 3216 (AU). MILNER, Peter, Gerard; 1001 Ray Avenue, Los Altos, CA 94022 (US). PFISTER, Jurg, Roland; 1500 Oak Avenue, Los Altos, CA 94024 (US). SCHREINER, George, Frederic; 12774 Leander Drive, Los Altos, CA 94022 (US).

(74) Agents: WHITLOCK, Ted, W. et al.; Saliwanchik & Saliwanchik, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL 32606-6669 (US).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71) UNIVERSITY OF FLORIDA
RESEARCH FOUNDATION, INC.
223 Grinter Hall
Gainesville FL 32611
United States of America

AUSTRALIAN 92153 18/10/95 PATENT OFFICE

(54) Title: NOVEL A_1 ADENOSINE RECEPTOR AGONISTS AND ANTIAGONISTS

(57) Abstract

Adenosine and xanthine derivatives, and compositions comprising those compounds, are potent selective agonists and antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias.

DESCRIPTION

NOVEL A_1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS

Cross-Reference to a Related Application

This application is a continuation-in-part of co-pending application Serial No. 08/144,459, filed October 28, 1993.

Background of the Invention

Adenosine is an extracellular messenger generated by all cells in the body. Adenosine itself, substances that mimic the actions of adenosine, and substances that antagonize its actions have important clinical applications. In the heart, an organ whose function depends critically on an adequate supply of oxygen, adenosine regulates the balance between oxygen supply (coronary blood flow) and oxygen demand (cardiac work). Adenosine released from working heart cells increases oxygen supply through coronary dilation and decreases oxygen consumption by slowing heart rate and modulating β-adrenergic stimulation. The protective effects of adenosine are particularly important when cardiac oxygen supply is limited, for example, by coronary artery narrowing.

Several recent reviews describe the adenosine system in detail (Belardinelli, L., J. Linden, R.M. Berne [1989] *Prog. Cardiovasc. Dis.* 32:73-97; Belardinelli, L., A. Pelleg [1990] *J. Cardiovasc. Electrophysiol.* 1:327-339; Olsson, R.A., J.D. Pearson [1990] *Physiol. Rev.* 70:761-845). The cardiac adenosine system consists of three processes: (1) mechanisms for adenosine formation; (2) adenosine receptors and proteins that couple them to effectors; and (3) mechanisms for the removal of adenosine. Selective modification of one or more of these systems by means of drugs such as adenosine receptor antagonists and adenosine uptake inhibitors can modify the actions of adenosine for therapeutic benefit.

Adenosine formation increases when oxygen demand exceeds its supply, thereby promoting the degradation of adenine nucleotides. The degradation of adenylates released from nerve terminals along with neurotransmitters and the

degradation of *S*-adenosylhomocysteine, a byproduct of methylation reactions, are additional sources of adenosine in the heart. Heart muscle and coronary blood vessel cells take up very nearly all the adenosine generated in the heart, reincorporating that adenosine into the cellular nucleotide pool.

At least two types of receptors mediate the actions of adenosine in the heart. A_1 adenosine receptors (A_1AR) decrease oxygen consumption, for example, by slowing heart rate, and A_2 adenosine receptors (A_2AR) increase oxygen supply by causing coronary vasodilation. The actions of adenosine on cardiac cells are either direct (cAMP-independent) or indirect (cAMP-dependent). The direct actions include the negative dromotropic effect on the AV node. Those electrophysiological effects are the basis of adenosine's anti-arrhythmic properties; adenosine is highly effective (>90%) in terminating paroxysmal supraventricular tachycardia (PSVT). The A_1AR-mediated inhibition of agonist-stimulated (but not basal) adenylate cyclase activity constitutes the indirect effects of adenosine. Whereas the direct effects of adenosine occur in the absence of agents that act through adenylate cyclase, the indirect effects reflect the inhibition of this enzyme when it is stimulated by agents such as β-adrenergic agonists.

A number of pharmacological studies employing receptor-selective agonists support the idea that A_2ARs mediate coronary vasodilation. Although endothelial cells contain A_2ARs and thus could play a role in vasodilation, they are not essential, for adenosine acts on coronary smooth muscle cells, causing them to relax.

When adenosine is used as a drug, its side effects are usually transitory, a reflection of its extremely rapid degradation in the body (seconds). The safety of adenosine in the diagnosis and treatment of PSVT is now well established. An important factor which has inhibited the therapeutic development of the adenosine analogues is the ubiquitous nature of adenosine's action on a variety of tissues.

Two kinds of drugs modify the actions of adenosine according to whether they magnify or attenuate the effects of the nucleoside. Inhibitors of the cell membrane nucleoside transporter block the removal of adenosine from the extracellular space, thereby increasing its concentration and intensifying its action. Adenosine uptake blockers also inhibit the nucleoside transport system in human erythrocytes and cardiocyte membranes and potentiate the cardiac actions of adenosine in the dog.

Methylxanthines competitively antagonize the binding of adenosine to both the A_1AR and the A_2AR. Certain naturally occurring methylxanthines such as caffeine and theophylline antagonize the cardiovascular effects of adenosine. For example, the administration of adenosine to patients receiving theophylline fails to produce AV block or terminate PSVT. However, those methylxanthines are relatively weak and, more importantly, are nonselective, antagonizing both the electrophysiological and vasodilatory effects of adenosine in laboratory animals and humans. Theophylline also ameliorates the non-cardiac effects of adenosine such as flushing, local pain, and respiratory stimulation.

Synthetic alkylxanthines, e.g., 8-cyclopentyl-1,3-dipropylxanthine (CPX; see U.S. Patent Nos. 4,364,922 and 4,980,379), are significantly more potent and selective antagonists at the A_1AR than are theophylline or caffeine.

Brief Summary of the Invention

The present invention concerns the discovery of certain novel compounds which can bind to adenosine receptors with surprisingly high affinity, specificity, and selectivity. Specifically exemplified herein are xanthine and adenosine analogues comprising an epoxide moiety. As explained in more detail herein, these adenosine agonists and antagonists have therapeutic utility in a broad range of applications including cardiac and renal regulation. Included among these novel compounds are both adenosine agonists and antagonists.

In one embodiment of the subject invention, the novel compound known as 1,3-dipropyl-8-{3-oxatricyclo[3.1.2.$0^{2,4}$]oct-6(7)-yl}xanthine, herein referred to as ENX, is used as an antagonist of adenosine. Advantageously, ENX has been found to be uniquely potent, specific, and highly selective for the A_1 adenosine receptor. Particular enantiomers of the ENX compound were synthesized and tested for their relative activity. Testing of *R*-and *S*-enantiomers of ENX revealed advantages of the *S*-enantiomers, namely, potency and selectivity for the A_1AR greater than those of the racemate or the *R*-enantiomer. However, the *R*-enantiomer, by virtue of its shorter biological half-life, can be advantageous in defined therapeutic applications requiring a short duration of action.

The present invention also concerns other preferred xanthines and adenosines comprising an epoxide moiety in an exocyclic substituent. Further embodiments of the invention include compositions and formulations comprising ENX or those analogs or derivatives which can have therapeutic utility as agonists or antagonists of adenosine.

A further aspect of the subject invention is a method for using the disclosed compounds for modulating the biological activity of adenosine. The compounds, or compositions comprising those compounds, can be utilized for their modulating effect on adenosine, e.g., as agonists or antagonists of adenosine receptors. The antagonist activity of the subject compounds can be utilized in treating conditions where elevated levels of adenosine are present; the agonists can be useful where stimulation of the adenosine receptor is needed. Such conditions include, but are not limited to, cardiac, renal, hepatic, or lung diseases, such as cardiac arrhythmias, renal failure, liver failure ascites, and asthma. Modulating adenosine activity can also be used in the treatment of maturity onset diabetes.

Brief Description of the Drawings

Figure 1 is a scheme outlining the syntheses of 1,3-dipropylxanthines having C-8 substituents that contain an epoxide moiety.

Figure 2 is a scheme for the synthesis of adenosine derivatives containing an epoxide moiety.

Figure 3 shows synthesis of (2*R*)- and (2*S*)- and (2*S*)-*endo*-5-norbornen-2-carboxylic acids.

Figures 4A-4D show selective antagonism of the negative dromotropic (S-H interval prolongation) effect of adenosine (Ado) by ENX. Figures 4A-4B show an analog record of the prolongation of the S-H interval (A_1 response, Figure 4A) and the increase in coronary conductance (A_2 response, Figure 4B) caused by a 3 minute infusion of adenosine (4 μM) in the absence and presence of 0.4 μM ENX. ENX inhibited the negative dromotropic effect of adenosine, but did not antagonize the coronary vasodilation (increase in coronary conductance) caused by adenosine. Figures 4C-4D show selective antagonism by ENX (0.4 μM) of the A_1 receptor-mediated increase in the S-H interval caused by adenosine (4 μM), but not the A_2 receptor

AUSTRALIAN

mediated coronary vasodilation. The values are the mean ± SEM from five guinea pig hearts. The asterisk is indicated by those values significantly different from adenosine alone ($P<0.05$).

Figures 5A-5D show a lack of effect of ENX on left ventricular pressure (LVP) and dP/dt_{max}. Guinea pig hearts were atrial paced at a constant cycle length of 300 msec and exposed to progressively higher concentrations of ENX, *i.e.*, 2 and 200 μM. In the same hearts ENX alone caused no significant changes in the stimulus-to-His bundle interval (not shown). Identical results were obtained in three other hearts.

Figure 6 shows the effect of ENX and isobutylmethylxanthines (IBMX) on phosphodiesterase (PDE) activity in homogenates of DDT_1MF-2 cells. The data for IBMX, shown as squares in the figure, clearly shows inhibition of phosphodiesterase activity. In contrast, phosphodiesterase activity following ENX administration, shown as circles in the figure, remained constant and showed no inhibition.

Figure 7 shows the specificity of action of ENX to antagonize the negative dromotropic effect (S-H prolongation) of adenosine in guinea pig heart. The effect of ENX (2 nM, 2 μM) on similar S-H prolongation caused by adenosine (ADO, 4 μM), magnesium (Mg^{2+}, 3 mM), and carbachol (CCh 0.14 μM) was determined. The height of each bar graph presents the mean ± SEM of 4 experiments. Only the S-H interval prolongation caused by adenosine was antagonized by ENX.

Figure 8 shows accumulative urine output in rats intravenously given 0.1 mg/kg of ENX (racemic) mixture; ENX (*R*-enantiomer); ENX (*S*-enantiomer); and a vehicle used as a control.

Detailed Description of the Disclosure

The subject invention pertains to novel compounds, and formulations comprising those compounds, which can advantageously be used as either agonists or antagonists at adenosine receptors. Specifically, these compounds either promote or antagonize the negative dromotropic, chronotropic, and inotropic effects mediated by an A_1 adenosine receptor (A_1AR). In the heart, these compounds can either promote or antagonize the negative dromotropic, chronotropic, and inotropic effects mediated by A_1AR, and in the kidney the antagonists promote diuresis through an A_1AR.

The subject compounds are of two general types: (1) 1,3-dialkylxanthines having C-8 substituents that comprise an epoxide (oxiranyl) moiety, and (2) adenosines having N-6 substitutents that comprise an epoxide moiety. In a preferred embodiment of the subject invention, the xanthine epoxides are 1,3-dialkylxanthines having an epoxide moiety covalently bound to the C-8 substituent of xanthine. The preferred epoxides of xanthine or adenosine are those having an epoxide moiety as part of an exocyclic substituent.

The general structure of one class of 1,3-dialkylxanthines is shown below as Formula I:

(I) 

wherein R_1 and R_2 are the same or different, and can be an alkyl group of 1-4 carbons in length; and n = 0-4. It would also be understood that R_1 and/or R_2 can be a hydrogen. Compounds which have one of the R-groups as hydrogen and the other R-group as an alkyl would be epoxides of alkyl xanthine; compounds having both R-groups as alkyls are epoxides of dialkylxanthine.

The general structure of the 1,3-dialkyl-8-oxatricycloalkylxanthines is shown below as Formula II:

(II) 

wherein R_1 and R_2 are the same or different, and can be a hydrogen or an alkyl group of 1-4 carbons; R_3 is either O or an alkyl group of 1-4 carbons; and n = 0-4.

A polymethylene chain 1-4 carbons in length can link the epoxide moiety to C-8 of 1,3-dialkylxanthine, as in Formula I. The epoxide group can also be part of an exocyclic substituent linked to C-8 of the xanthine moiety, either directly or

through a (poly)methylene chain 1-4 carbons long, as in Formula II. The exocyclic substituent, shown as Formula II, can be a bicycloalkyl group, forming an oxatricycloalkyl substituent. Other exocyclic epoxide structures can also be part of the compound as would be readily recognized by those skilled in the art having the benefit of this disclosure. The bicycloalkyl group can further contain an alkenyl group for the formation of a second epoxide moiety.

Figure 1 depicts a general synthesis scheme for the 8-substituted 1,3-dipropylxanthines.

A preferred embodiment of the subject invention is a compound having the chemical name 1,3-dipropyl-8-{3-oxatricyclo[3.1.2.$0^{2,4}$]oct-6(7)-yl}-xanthine, which is commonly termed epoxynorbornylxanthine, or ENX. The formula for ENX is shown as Formula III, below:

(III)



ENX has been demonstrated to have advantageous and unexpected properties as an adenosine antagonist by its high selectivity and affinity for the A_1 adenosine receptor.

Essentially, a patient who has any condition where levels of endogenous adenosine are, or could become, excessive can benefit from therapeutic use of the subject antagonist compound or a composition comprising the compound. For example, the subject invention pertains to the use of the subject antagonist compounds as diuretics or in the treatment of renal failure. In addition, the subject antagonist compounds or compositions comprising these compounds can be employed in the treatment of certain conditions affecting the heart, including bradyarrhythmias associated with hypoxia or ischemia (myocardial infarction), sick sinus node syndrome, and in heart failure, where the positive inotropic effect of the antagonist can be advantageous. Other conditions which are recognized as resulting from, or affected by, elevated levels of endogenous adenosine can also be treated with the subject adenosine antagonists.

The high selectivity and affinity for A_1 adenosine receptor exhibited by the subject compounds, *e.g.*, ENX, make them particularly useful as diuretics. The potency of ENX as a diuretic has been demonstrated to be at least as high as the potency of furosemide (Lasix), a commonly used diuretic in human and animal medicine. Thus, it would be understood that ENX could be used in a manner comparable to the way furosemide is used to produce a diuretic effect in a patient.

The diuretic activity exhibited by ENX can be exploited in the treatment of several conditions commonly affecting mammals, especially humans. For example, congestive heart failure (CHF) is a condition in which diuretics are extensively used. Hypertension, often a concurrent condition with CHF, is also regularly treated with diuretics. ENX was shown to have comparable diuretic activity and potency as currently marketed diuretics, *e.g.*, Lasix, used for treatment of such conditions. Thus, the subject compounds, especially ENX, can be used in a similar manner for treatment of these conditions.

The subject adenosine antagonists can also be indicated as nephroprotecting compounds. ENX, which has been shown to bind to the A_1 adenosine receptor, can be used to block those receptors during the use of contrast agents known to be nephrotoxic, or can be useful in treatments to counteract the nephrotoxic effects of certain antibiotics, *e.g.*, gentamycin, amphotericin, or cyclosporin.

In addition, the subject A_1 adenosine antagonists, *e.g.*, ENX, can be useful for treatment of the ascites of liver failure. As would be readily understood in the art, ENX can be useful with certain modifications of treatment regimens and indications for non-transplant patients suffering from liver failure, pre-transplant patients, or for transplant patients having hepato-renal syndrome.

The activity as an adenosine A_1 receptor inhibitor and diuretic indicates that the subject antagonist compounds, *e.g.*, ENX, also can be used as an analgesic, especially in the treatment of angina, claudication, and bradyarrhythmias associated with ischemia, hypoxia, or reperfusion. Also, the use of exogenously administered adenosine in cardiac diagnostic procedures, *e.g.*, imaging of cardiac vasculature, is known to produce transitory side effects, including a brief onset of pain. As this side effect has been attributed to adenosine's binding to, and stimulation of, the A_1 receptor (but not the A_2 receptor), an adenosine antagonist inhibiting the binding of adenosine

to that A_1 receptor can be used to counteract the pain experienced by a patient undergoing the procedure. The subject compounds, including ENX, selectively bind to the A_1 adenosine receptor, inhibiting the binding of adenosine (and thus blocking or counteracting any side effect associated with the binding of adenosine to the A_1 receptor).

Further, the subject antagonist compounds, including ENX, can be used as a bronchodilator, *i.e.*, an antiasthmatic. ENX has been shown to relax tracheal smooth muscle, thus producing bronchodilation. This property is also common to other much weaker xanthine derivatives, *e.g.*, theophylline. Such use of the subject antagonist compounds as an antiasthmatic treatment suggests that the compound can be useful when administered via an inhalation route.

Other routes of administration of the subject compounds can also be used. For example, it is generally contemplated to administer the compounds according to the optimal route indicated for the condition being treated. Thus, the compounds can be administered intravenously, *per os*, transdermally, etc., and in single or multiple dosage regimens, as would be understood by a person of ordinary skill in the art.

It would also be understood by ordinarily skilled artisans that the above-described uses for the subject compounds can be optimized by using particular isomers which demonstrate different biological activities. Having a chiral center, ENX is recognized to exist in at least two enantiomeric forms. The ENX enantiomers, namely, the *S*-enantiomer and the *R*-enantiomer, have been synthesized as the *R*- and *S*- isomers of 5-norbornene-2-carboxylic acid by methods available in the art. See Poll, T. *et al.* (1985) *Tetrahedron Lett.* 26:3095-3098, and Poll, T. *et al.* (1989) *Tetrahedron Lett.* 30:5595-5598. The *endo-R*- and *endo-S*-enantiomers of ENX are shown as Formulas IV and V, respectively.



IV



V

Studies conducted on the two enantiomers of ENX show that both are selective for the A_1AR as compared to the A_2AR. The *S*-enantiomer has a longer duration of action than the *R*-enantiomer. Although a racemic mixture of the *R*- and *S*-enantiomers can have the biological activity of either or both isomers, it is now understood that the *S*- and *R*- isomers can be used separately, as a single enantiomer, to effect particular advantageous activities of either enantiomer.

For example, about 80-90% of the biological activity demonstrated by a racemic mixture of ENX is accounted for by the *S*-enantiomer. This result is primarily due to the very short duration of activity by the *R*-enantiomer as compared to the duration of action exhibited by the *S*-enantiomer. The prolonged action of the *S*-enantiomer can be due to a slower clearance rate in the liver, *e.g.*, slower metabolic degradation by enzyme systems such as cytochrome P_{450}. The *S*-enantiomer, which showed slightly increased potency *in vitro* as compared to the *R*-enantiomer, showed substantially higher potency *in vivo*, and consequently higher selectivity for the A_1 adenosine receptor as compared to the A_2 receptor. See Example 4 for specific data comparing the selectivity and affinity properties of the *S*- and *R*-enantiomers of ENX.

The advantageous properties, *e.g.*, increased potency (*in vitro* and *in vivo*) and higher selectivity, as well as the longer duration of action exhibited by the *S*-enantiomer, indicates that the *S*-enantiomer can be very useful as a diuretic in animals and humans. In most instances, as those exemplified above, the *S*-enantiomer can be the preferred compound because the length of its duration of activity, which is more

than that of the *R*-enantiomer, can be critical to achieving its effect. In other words, the compound must at least cause an effect long enough to accomplish the desired result.

On the other hand, in instances where short duration of action are desired, *e.g.*, during intravenous infusion of adenosine or onset of myocardial ischemia, when the onset of increased adenosine levels is rapid and lasts only for a short period of time (on the order of seconds or minutes), an adenosine antagonist having a short duration of action, *e.g.*, the *R*-enantiomer of ENX, can be advantageously used. The activity of the ENX *R*-enantiomer is beneficial for short periods of time. However, the *R*-enantiomer of ENX is rapidly degraded or metabolized. This rapid metabolism can prevent complications associated with drug interactions because the concentrations of the ENX *R*-enantiomer are rapidly decreased. Due to its analgesic properties, the *R*-enantiomer of ENX can be administered for the acute pain of angina.

Another application of the subject compounds having a short duration of action is as an antiasthmatic or bronchodilator. It has been suggested that the high biological activity shown for the *S*-enantiomer of ENX is due to the rapid and selective metabolism of the *R*-enantiomer of ENX in the liver. This can be due to a first-pass effect exhibited for the *R*-enantiomer when administered by routes in which the drug is degraded by liver enzymes prior to or at about the same time as it reaches the appropriate receptors where the pharmacologic effect is induced. However, certain other routes of administration can be advantageously used to exploit this first-pass effect. For example, the *S*- and *R*-enantiomers of ENX have been demonstrated to be bronchodilators. Administration of the *R*-enantiomer alone (or in a composition comprising the *R*-enantiomer but not the *S*-enantiomer) by inhalation immediately presents the compound to the appropriate receptors in the trachea and bronchi to cause its action. Any absorbed compound is rapidly eliminated, which reduces residual levels of the compound in the body.

Derivatives of adenosine containing an epoxide moiety, particularly those having an epoxide moiety in an N-6 substituent, can be used as A_1AR agonists. Epoxide derivatives of adenosine agonists can also display high selectivity for adenosine receptors. High selectivity for cardiac tissue is also demonstrated. More

specifically, N^6-substitution of adenosine with epoxycycloalkyl groups can result in potent and tissue-selective agonists.

The N^6-subregion of the A_1 adenosine receptor contains chiral recognition sites which can be important for the determination of A_1/A_2 selectivity. The epoxide can be substituted as a cycloalkyl substituent, e.g., cyclopentyl, norbornanyl, or adamantanyl derivative of adenosine. Shown below as Formula VI is an adenosine epoxide having the epoxide substituent at the N^6 position. The epoxide can be attached as a cyclopentyl or norbornanyl group.

(VI) 

wherein R = 

or



and R_1 = an alkyl group of 1-4 carbons. The compound can be one of four isomers: the 2*R-endo*, 2*R-exo*, 2*S-endo*, or the 2*S-exo* form.

Biological activity can also be enhanced by modifying other parts of the cycloalkyladenosine molecule. For example, both 2- and 5′-chloro substitutions of N^6-cycloalkyladenosines have been used to increase A_1 selectivity. Figure 2 shows the steps involved in chemically converting an adenosine molecule or its derivative to an adenosine compound comprising an epoxybicycloalkyl group as an N^6 substituent. Preferably, dimethyldioxirane is the oxidant used in the formation of the

epoxide of the adenosine compound. See Iyer, R.S. *et al.* (1994) *J. Am. Chem. Soc.* 116:1603-1609. The dimethyldioxirane can be made according to methods and procedures known in the art. See Murray, R.W., R. Jeyaraman (1985) *J. Org. Chem.* 50:2847-2853; Adam, W. *et al.* (1991) *Chem. Ber.* 124:2377.

The subject adenosine agonists can be useful for the treatment of a patient where stimulation of A_1AR is needed. Uses for the subject adenosine agonists and compositions comprising those agonists include their use as a functional β-blocker; as an antiarrhythmic agent for the control of heart rate, including supraventricular tachyarrhythmias, catecholamine (cAMP-dependent) supra- and ventricular-arrhythmias; diabetes type II; and cardioprotection, e.g., decrease infarct size and increase tolerance to myocardial ischemia.

The compounds of the subject invention (agonists and antagonists) can be formulated with a pharmaceutically acceptable carrier into a composition that can be administered to a patient who would benefit from the adenosine receptor agonist or antagonist properties of the subject compounds or compositions.

Advantageously, dosages of the subject adenosine antagonists for treating post-resuscitation cardiac arrhythmias can be less than the 0.1-20 mg/kg range which has been previously reported for known adenosine antagonists. See U.S. Patent No. 4,980,379. An effective dose can be recognized as the dose at which the alleviation of bradycardia and reversal of hemodynamic collapse occurs.

Standard procedures for administration of adenosine antagonists such as theophylline and aminophylline at effective dosage levels are well established and are well known to those skilled in the art. For example, the recommended therapeutic range for plasma levels of theophylline for patients with reversible obstruction of the airways is from 10-20 μg/ml. The subject compounds, having high selectivity and potency, can be useful and effective at known concentrations in the blood.

The above list of treatment uses for the subject compounds or compositions is by no means exhaustive, and other situations where the subject invention could be advantageously employed would be readily recognized by ordinarily skilled persons in this art. For example, it would be readily recognized in the art that other conditions which can be treated by reducing the effects of elevated endogenous adenosine or by

increasing stimulation of the A_1AR can also benefit from the use or administration of the subject adenosine antagonists or agonists, respectively.

Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1 - Preparation of 8-Epoxyalkylxanthines

Chemistry. The scheme shown in Figure 1 outlines the syntheses of 1,3-dipropylxanthines having C-8 substituents comprising an epoxide moiety. The reaction of 5,6-diamino-1,3-dipropyluracil, **1**, with an ω-alkenoyl halide or an ω-alkenoyl ester gave an amide **2**, which was then cyclized in hot alkali to form the 8-ω-alkenyl-1,3-dipropylxanthine **3**. Oxidation with *m*-chloroperbenzoic acid yielded the 8-epoxyalkylxanthine **4**. Alternatively, the Diels-Alder condensation of **3** with a 1,3-cycloalkadiene generated an 8-bicycloalkenylxanthine **5**. When furan was the alkadiene the product was the 8-ω-{7-oxabicyclo[2.2.1]hept-2-en-5(6)-yl}xanthine **5**, which contains both (a) an epoxide moiety and (b) an alkenyl moiety that can serve for the formation of a second epoxide moiety. The oxidation of **5** with 2.4 equivalents of *meta*-chloroperbenzoic acid gave the 8-epoxybicycloalkylxanthine **6**.

1,3-dipropyl-8-{3-oxatricyclo[3.2.1.$0^{2,4}$]oct-6(7)yl}xanthine. A solution of 8-bicyclo[2.2.1]hept-2-en-5(6)ylxanthine (1.0 g, 3 mmol) and *m*-chloroperbenzoic acid (0.8 g, 3.6 mmol) in 50 ml CH_2Cl_2 was stirred for 24 hours at room temperature. A second aliquot of peracid was added and stirring continued for 24 hours. Evaporation gave a yellow oil that was purified by preparative reverse phase HPLC on C-18 silica eluted with a gradient of 70-80% methanol in water. Yield 0.54 g, 52%, mp 149-150°C.

1,3-dipropyl-8-{7-oxabicyclo[2.2.1]hept-2-en-5(6)yl}xanthine. A suspension of 1,3-dipropyl-8-vinylxanthine (0.4 g, 1.5 mmol) in 50 ml dry THF containing furan (0.22 ml, 3 mmol) was stirred at room temperature. The addition of 1 drop of TMS triflate effected solution, and HPLC showed the disappearance of starting material.

Preparative reverse phase HPLC on C-18 silica eluted with a gradient of 50-80% methanol in water yielded 0.25 g (50%) of product.

Example 2 -Preparation of an Adenosine Derivative Comprising an Epoxide Moiety

A compound useful as an adenosine agonist is an adenosine derivative comprising an oxabicyclo- or oxatricycloalkyl group as an N-6 substituent. A general scheme for the preparation of the compound is shown in Figure 2.

N^6-*endo*-{3-oxatricyclo[3.2.1.$0^{2,4}$]oct-6(7)-yl}adenosine. A solution of N^6-(*endo*-2-norbornene-5-yl)adenosine (0.5 g, 1.4 mmol) in 100 mL dry methanol was cooled to 0-5°C in an ice bath, a solution of dimethyldioxirane in acetone (40 mL, 4 mmol) was added; stirring continued for 8 hours in the ice bath and then overnight at room temperature. Evaporation of solvent and purification by chromatography yielded 0.42 g (81%) of a white solid.

Example 3 - Use of the Novel Compounds as Adenosine Antagonists

In order to demonstrate the effectiveness of the subject compounds as adenosine antagonists, the activity of the compounds was compared to known antagonists. In addition, the specificity, selectivity, and potency of ENX as an A_1 adenosine receptor antagonist, functional and biochemical (radioligand binding assays) experiments were carried out on guinea pig isolated hearts, in membranes from guinea pig brain, DDT$_1$MF-2, and PC12 cells. The results of these experiments are described below.

1. Functional studies. The functional evidence that an epoxide of alkylxanthine (ENX) specifically and selectively antagonizes cardiac actions of adenosine mediated by A_1-adenosine receptor but does not antagonize A_2-adenosine-receptor mediated coronary vasodilation was obtained in the isolated perfused guinea pig heart. The effect of ENX and two other alkylxanthines (NAX and CPX) on the A_1-receptor mediated changes in stimulus-to-His bundle interval (S-H interval; a measure of AV nodal conduction) and on the A_2 receptor mediated coronary vasodilatation were investigated. The potency of ENX, NAX, and CPX to antagonize the negative dromotropic (prolongation of S-H interval) of the A_1 agonist CCPA and vasodilatory effect of adenosine are shown in Tables 1 and 2.

Table 1. Potency of various alkylxanthines to antagonize A_1 receptor-mediated cardiac response: results of Schild analysis.

	ENX	NAX	CPX
PA_2	8.45 ± 0.19	8.79 ± 0.15	8.76 ±0.02
K_B	3.6 nM (1.2-3.9)	1.6 nM (1.1-3.2)	1.7 nM (1.6-1.9)
Slope	−0.91 ± 0.06	−0.89 ± 0.11	−0.81 ± 0.03
n	4	3	3

Values are mean ± S.E.M. of the PA_2 ($-\log_{10}K_B$), the equilibrium dissociation constant K_B, and the slope of Schild plot. Cardiac response: antagonism of the negative dromotropic effect of the selective A_1 agonist CCPA. The numbers in parentheses are the minimum and maximum K_B values. n = number of experiments. Neither the PA_2 (K_B) nor the slope of Schild plots were significantly different among the antagonists.

Table 2. Potency of various alkylxanthines to antagonize A_2 receptor-mediated coronary vasodilation.

	ENX	NAX	CPX
IC_{50}	no effect (0% at 50 μM)	7.1 μM (4.8-9.4)	1.5 μM (0.8-2.2)
n	4	3	3

Values are the concentration of antagonist that inhibits 50% (IC_{50}) of a maximum coronary vasodilation caused by adenosine. Values in parentheses are 95% confidence interval of the IC_{50} values. n = number of experiments.

Although all three alkylxanthines were equipotent in antagonizing the A_1-receptor mediated prolongation of the S-H interval, ENX is far more selective than NAX and CPX.

To further demonstrate the selectivity of ENX for A_1 vs A_2 receptor, measurements of A_1-receptor mediated S-H interval and A_2-receptor mediated increase in coronary conductance were carried out during administration of adenosine alone and adenosine plus ENX (Figures 4A-4D). Adenosine (Ado, 4 μM), when administered alone, produced a significant increase in S-H interval and coronary conductance. When adenosine was administered together with ENX (0.4 μM), the S-H interval

prolongation was completely inhibited, whereas the A_2-mediated coronary vasodilation remained unaltered. After washout of ENX, a third administration of adenosine alone caused a significant prolongation of S-H interval (similar to the first administration of adenosine) and increase in coronary conductance. These findings demonstrate that the effects of ENX are reversible and that ENX antagonizes the A_1-receptor mediated S-H prolongation but not the A_2-receptor mediated increase in coronary conductance caused by adenosine. These data also demonstrate the capability of ENX to inhibit activity (and thus any side effects) associated with the binding of adenosine to the A_1 receptor while the beneficial pharmacological activity of adenosine stimulation of the A_2 receptor remains unaffected.

To determine whether ENX had a positive inotropic effect, experiments were conducted to determine its effects on left ventricular pressure (LVP) and its first derivative dP/dt, an index of contractility. As illustrated in Figure 5, there were no significant changes in either LVP or dP/dt of normoxic guinea pig hearts when these hearts were exposed to increasing concentrations of ENX (2-200 μM). LVP and dP/dt remained constant during the administration of varying concentrations of ENX and washout. These results demonstrate the lack of a positive inotropic effect of ENX.

Consistent with the lack of positive inotropic effect, ENX also did not inhibit the enzyme phosphodiesterase (Figure 6). Cells were homogenized in 40 mM Tris buffer at pH 8.0, and the whole homogenate was used in the enzyme assays. PDE activity was determined by incubating homogenate (0.4 mg protein) in Tris buffer containing 20 mM $MgCl_2$, 4 mM mercaptoethanol, 0.06 mg bovine serum albumin, 0.4 mM cAMP 130 nCi of [^{3}H]cAMP and the indicated concentrations of ENX or IBMX for 45 min at 30°C. Blank incubations were carried out in parallel assays without the homogenate. At the end of the incubation, the suspensions were incubated in a boiling water bath for 2 minutes, transferred to an ice-water bath for 2 minutes and 0.1 mg of snake venom phosphodiesterase was added. The suspensions were incubated for 10 minutes at 30°C, and the adenosine formed was isolated by ion exchange chromatography. The control rate of adenosine formed was 220 pmol/mg protein per minute. The amount of adenosine formed was linear over the incubation period used.

Agents that inhibit the enzyme phosphodiesterase are known to produce positive inotropic effect. The results illustrated in Figure 6 clearly showed that ENX

does not inhibit phosphodiesterase, whereas isobutylmethylxanthine (IBMX, a known positive inotropic agent) inhibits phosphodiesterase. These findings demonstrate an advantage of ENX over other alkylxanthines that are known to inhibit phosphodiesterase, and therefore have the potential to produce a positive inotropic action.

Carbachol and $MgCl_2$ were used to test the specificity of antagonism by ENX, *e.g.*, S-H interval prolongation mediated by adenosine As illustrated in Figure 7, ENX (2 nM, 2 μM) did not antagonize the negative dromotropic effect of carbachol or $MgCl_2$. In contrast, ENX did antagonize the S-H prolongation caused by adenosine.

In summary, the results of the functional experiments described above demonstrate that in the heart, ENX is a reversible, specific, and highly selective antagonist of adenosine at the A_1 receptor subtype.

2. Radioligand binding studies. To determine the binding affinities of an epoxide of alkylxanthine, ENX, and compare to other alkylxanthines (CPX, NAX and CPT), radioligand binding experiments were carried out in membranes prepared from brain tissue, DDT_1MF-2 and PC12 cell lines. The results of these experiments are illustrated in Tables 3 and 4. The results summarized in Table 3, below, indicate that in brain tissue, ENX is more potent than the other alkylxanthines at the A_1AR, whereas in DDT_1MF-2 cell the binding affinity of the alkylxanthines for the A_1 receptor are approximately the same. With regard to A_2 receptors in PC12 cell membranes, ENX was markedly less potent than CPX. In addition, the binding affinity of ENX for the A_1 receptor, either brain or DDT_1MF-2 cells, was markedly higher than that at the A_2 receptor in PC-12 cell membranes.

Table 3. Binding affinities of alkylxanthines for the A_1- and A_2-adenosine receptors in brain, DDT_1-MF_2 and PC-12 cell membranes

Alkylxanthine	K_i (nM)		
	Brain	DDT_1MF_2	PC-12
ENX	0.45 ± 0.02 (5)	0.22 ± 0.03 (5)	11,666 ± 366 (4)
CPX	4.4 ± 0.8 (4)	0.13 ± 0.01 (4)	320 ± 40 (3)
NAX	3.8 ± 0.21 (4)	0.18 ± 0.05 (3)	----------
CPT	41.0 ± 13.0 (4)	----------	----------

A_1 receptor binding was carried out with [^{3}H]CPX in guinea pig forebrain and cardiac membranes, and in intact DDT_1-MF_2 cells. A_2 receptor binding was carried out with [^{3}H]NECA in PC-12 cell membranes. Values are mean ± SEM of triplicate determinations in each of several (n) preparations. K_i values were calculated as described in methods. Abbreviations for the alkylxanthines are as follows: ENX = 1,3-dipropyl-8-{3-oxatricyclo[3.1.2.0^{2,4}] oct-6(7)-yl}xanthine; CPX = 8-cyclopentyl-1,3-dipropylxanthine; NAX = 1,3-dipropyl-8-(3-noradamantyl)xanthine; and CPT = 8-cyclopentyl-1,3-dimethylxanthine.

Additional radioligand binding studies have been carried out in guinea pig forebrain (A_1 receptor) and striatum (A_2 receptor) to demonstrate the greater A_1 receptor selectivity of ENX as compared to the previously known adenosine receptor antagonists, NAX or CPX. Table 4 shows A_1 and A_2 receptor binding affinities of brain tissue expressing A_1 (forebrain) and A_2 (striatum) adenosine receptors. The results of Table 4 clearly illustrate that ENX is significantly more selective for A_1 than A_2 receptors than the other alkylxanthines, NAX and CPX. That is, ENX was 800-fold selective for A_1 vs. A_2, whereas NAX and CPX were only 20 and 7.5 fold selective for A_1 vs. A_2, respectively. These results of these radioligand binding studies are fully consistent with that of the functional studies in guinea pig isolated hearts.

Table 4. Binding affinities of alkylxanthines for the A_1 and A_2 adenosine receptor in brain membranes

Alkylxanthine	K_i (nM)		
	A_1 (forebrain)	A_2 (striatum)	Ratio A_1/A_2
ENX	0.45 ± 0.13	360 ± 36	800
NAX	1.10 ± 0.15	22 ± 6.90	20
CPX	8.4 ± 3.00	63 ± 5.40	7.5

A_1 and A_2 receptor binding was carried out with [^{3}H]CPX and [^{3}H]CGS 21,860 in guinea pig forebrain and striatum, respectively. Values are mean ± S.E.M. of triplicate determinations in each of four preparations.

Example 4 — Activities of ENX Enantiomers

The *S*-enantiomer and *R*-enantiomer of ENX were synthesized, as described, and tested for their relative activities and potencies. As shown in Table 5, below, the lower dissociation constant of the *S*-enantiomer of ENX suggests slightly higher potency (K_i=0.98) as compared to the *R*-enantiomer (K_i=2.1).

Table 5. Equilibrium dissociation constants of ENX enantiomers and CPX for rat brain A_1 adenosine receptors.

Compound	K_d or K_j, nM
[^{3}H]CPX	0.49
R-ENX	2.1
S-ENX	0.98

In addition, the *S*-enantiomer of ENX demonstrated higher binding selectivity for the A_1 receptor. See Table 6, below.

Table 6. Potency and selectivity of ENX to antagonize radioligand binding to rat brain adenosine A_1 and A_2 receptors ("IC_{50}"* values)

	A_1	A_2	Selectivity
ENX (racemate)	1.65 nM	2.1 μM	1300
S-ENX	1.15 nM	9.0 μM	7800
R-ENX	2.70 nM	2.6 μM	960

*"IC_{50}" refers to the concentration at which radioligand binding to receptors was 50% inhibited.

The increased potency of the *S*-enantiomer is shown in Figure 8. As shown, most of the diuretic activity exhibited by ENX as a racemic mixture resided in the *S*-enantiomer. Specifically, Figure 8 shows a cumulative urine output measured for a period of 2 hours in rats administered 0.1 mg/kg ENX racemate, ENX *R*-enantiomer, and ENX *S*-enantiomer. It is therefore shown that, as a diuretic, the *S*-enantiomer of ENX is more potent than the *R*-enantiomer of ENX or a racemic mixture of *R*- and *S*-enantiomers of ENX. The duration of action is also longer for the *S*-enantiomer of ENX. These properties of the ENX *S*-enantiomer suggest its preferable use as a long-lasting diuretic in treating conditions normally calling for administration of a diuretic. Standard pharmacologic screening tests showed that the *S*-enantiomer of ENX (100 mg/kg *per os*) relaxed constricted guinea pig tracheal muscle. The *S*-enantiomer of ENX reduced serum cholesterol and heparin precipitating β-lipoproteins in mice after 100 mg/kg *per os*. Of interest, the observed reduction in HPL/CHOL ratio below 0.92 suggests a possible decrease in atherogenic low density β-lipoproteins.

Saluretic activity associated with increased urine volume output was observed in the hydrated rat at doses of and above 3 mg/kg *per os*. Moderate kaluretic activity was also noted after 30 mg/kg *per os* in this preparation, suggesting potassium sparing diuretic activity.

The *R*-enantiomer was shown to have activity as an antagonist of adenosine. Specifically, the *R*-enantiomer was observed to induce relaxation of spontaneous tone in guinea pig trachea. Saluretic activity associated with increased urine volume output was observed in the hydrated rat at 10 mg/kg *per os* of the ENX *R*-enantiomer. However, the activity of the ENX *R*-enantiomer has a very short duration of action as

compared to the *S*-enantiomer. However, that can be useful in treating conditions that indicate short-acting treatments.

Example 5 — Synthesis of N^6-Substituted Adenosine Derivatives

The subject agonist compounds shown as Structure IV can be synthesized according to known procedures. For example, the general synthesis scheme for obtaining these compounds initially involves alkylation of an appropriately substituted amine, e.g., a bicyclic amine, with 6-chloropurine riboside. This straightforward reaction has been commonly used for the synthesis of N^6-substituted adenosines. See WO 84 04 882 (1985).

The substituted amine can be functionalized with a double bond which can then be oxidized to generate the epoxide product. *m*-Chloroperbenzoic acid can be used for this oxidation reaction. See also Sharpless, K.B., W. Amberg, Y.L. Bennani, G.A. Crispino, J. Hartung, K.-S. Jeong, H.-L. Kwong, K. Morikawa, Z.-M. Wong, D. Xu, X.-L. Zhang (1992) *J. Org. Chem.* 57:2768-2771; and Kolb, H.C., B.K. Sharpless (1992) *Tetrahedron* 48:1015-1030.

An alternative method of generating epoxides is the osmium-catalyzed dihydroxylation of olefins, which is now well known in view of the discovery of phthalazine ligands and that osmate ester hydrolysis is acceleration by organic sulfomamides. A simple, one-pot procedure for the conversion of vicinal diols into epoxides is known in the art (Kolb, H.C., B.K. Sharpless, *supra*). This reaction proceeds without epimerization via halohydrin ester intermediates. Combination of these methods allows epoxides to be obtained from olefins in a stereospecific fashion.

The substituted amines which can be used for synthesis of the subject compounds shown as Structure IV are 3-cyclopenten-1-yl amine (for the cyclopentene oxide derivative of adenosine) or 5-norbornen-2-yl amine (for the cyclohexene epoxide derivative of adenosine). 3-Cyclopenten-1-yl-amine can be synthesized from *cis*-1,4-dichlorobutene and diethyl malonate via a 5-step reaction sequence which is known in the art (Murdock, K.C., R.B. Angier [1962] *J. Org. Chem.* 27:2395-2398).

The synthesis of 5-norbornene-2-yl amine proceeds from 5-norbornene-2-carboxylic acid, commercially available as a mixture of four isomers, 2*R* and 2*S*, each *endo* and *exo*. Conversion of this carboxylic acid to acyl chloride, followed by

treatment with sodium azide, yields an acyl azide. Curtius rearrangement (loss of N_2 and migration of the substituent group) and subsequent hydrolysis yields 5-norbornen-2-yl amine as a mixture of isomers. This reaction sequence can be performed as a continuous operation without the isolation of the acyl azide or isocyanate in the synthesis of 4-aminocyclohexene. Another variation used for the Curtius rearrangement involves the preparation of the acyl azide by treatment of the corresponding acyl hydrazine with nitrous acid. In both cases, the rearrangement retains the absolute configuration at the chiral center. The *endo* and *exo* components can be separated by HPLC methods known in the art.

The synthesis of the optically pure 5-norbornen-2-yl amines involves the use of asymmetric Diels-Alder reactions to obtain intermediate carboxylic acids, followed by a Curtius rearrangement as described above. A general scheme for synthesizing these compounds is shown in Figure 3.

Example 6 – Uses, Formulations, and Administrations

Therapeutic and prophylactic application of the subject compounds, and compositions comprising them, can be accomplished by any suitable method and technique presently or prospectively known to those skilled in the art. Further, the compounds of the invention have use as starting materials or intermediates for the preparation of other useful compounds and compositions. The compounds of the invention are useful for various non-therapeutic and therapeutic purposes. It is apparent from the testing that the compounds of the invention have effective antiarrhythmic activity. Specifically, they are useful in regulating cardiac arrhythmia, including PVST, in animals and humans.

The demonstrated effects of both the agonists and the antagonists on cardiac chronotropy, dromotropy, and inotropy make them useful therapeutically as either stimulants or modulators of cardiac performance, thereby affecting function of the heart. For example, the regulation or modulation activity of the subject compounds can affect heart rate (chronotropic effect) and impulse conduction (dromotropic effect). The subject compounds can also be used diagnostically to determine parameters of cardiac function, e.g., as pharmacological reagents useful in determining whether adenosine receptors are mediators of dysfunction of the heart or other organs.

The subject compounds can also serve as standards for *in vitro* and *in vivo* studies that measure or compare activities of other agonists and antagonists that act directly or indirectly through adenosine receptors. As reagents for such comparisons, the compounds are valuable pharmacological tools. Their high affinity and selectivity for the A_1 adenosine receptor make them important sources of information about the function of those receptors throughout the body.

Other uses for the subject compounds include their use in the characterization of structure or location of adenosine receptors in organs or tissues. This can be done by, for example, attaching an appropriate label or reporter to the subject compounds by standard techniques or procedures known to persons of ordinary skill in the art. The labels that are suitable for conjugation to the compounds of the subject invention include, but are not limited to, radiolabels (e.g., radioisotopes), fluorescent labels, and biotin labels. Radioisotopes that are suitable for labeling the subject compounds include Bromine-77, Fluorine-18, Iodine-131, Iodine-123, Iodine-125, Iodine-126, Iodine-133, Indium-111, Indium-113m, Gallium-67, Gallium-68, Ruthenium-95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-107, Mercury-203, Rhenium-99m, Rhenium-105, Rhenium-101, Technetium-99m, Tellurium-121m, Tellurium-99m, Tellurium-125m, Thulium-165, Thulium-167, Thulium-168, and Tritium. The gamma-emitting Indium species and Technetium-99m are preferred isotopes because these isotopes are detectable with a gamma-camera and have favorable half lives for imaging *in vivo*. Alternatively, it would be recognized by those of ordinary skill in the art that non-radioactive labels, for example, enzyme-substrate complexes, e.g., biotin-avidin, horseradish peroxidase—alkaline phosphatase, and the like could be used. Also, fluorescent entities suitable for labeling the subject compounds include fluorescein sodium, fluorescein isothiocyanate, and Texas red sulfonyl chloride. As such, the compounds can be used to visualize, *in vitro* or *in vivo*, structure or function of organs or tissues in which the A_1 adenosine receptors are present.

A further embodiment of the subject invention involves the use of the compounds to direct therapeutic compounds to the A_1 adenosine receptor site. Because of the specificity of the compounds of the subject invention, they can be conjugated to therapeutic compounds in order to direct the therapeutic compound to the vicinity of A_1 adenosine receptor. Also, in the case of compounds of the subject

inventions which have selectivity to a specific type of tissue, such as heart tissue, these compounds can be used to direct therapeutic or diagnostic reagents to those locations.

The administration of the subject compounds of the invention is useful as an antiarrhythmic agent. Thus, pharmaceutical compositions containing compounds of the invention as active ingredients are useful in prophylactic or therapeutic treatment of cardiac arrhythmias in humans or other mammals.

The dosage administered will be dependent upon the antiarrhythmic response desired; the type of host involved; its age, health, weight, kind of concurrent treatment, if any; frequency of treatment; therapeutic ratio and like considerations. Advantageously, dosage levels of the administered active ingredients can be, for examples, dermal, 1 to about 500 mg/kg; orally, 0.01 to 200 mg/kg; intranasal 0.01 to about 100 mg/kg; and aerosol 0.01 to about 50 mg/kg of animal body weight.

Expressed in terms of concentration, the active ingredient of the invention can be present in the new compositions for use dermally, transdermally, intranasally, bronchially, intramuscularly, intravaginally, intravenously, or orally in a concentration of from about 0.01 to about 50% w/w of the composition, and especially from about 0.1 to about 30% w/w of the composition. Preferably, the novel compound is present in a composition from about 1 to about 10% and, most preferably, the novel composition comprises about 5% novel compound.

The compositions of the invention are advantageously used in a variety of forms, e.g., tablets, ointments, capsules, pills, powders, aerosols, granules, and oral solutions or suspensions and the like containing the indicated suitable quantities of the active ingredient. Such compositions are referred to herein and in the accompanying claims generically as "pharmaceutical compositions." Typically, they can be in unit dosage form, namely, in physically discrete units suitable as unitary dosages for human or animal subjects, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic or prophylactic effect in association with one or more pharmaceutically acceptable other ingredients, e.g., diluent or carrier.

Where the pharmaceutical compositions are aerosols, the active ingredients can be packaged in pressurized aerosol containers with a propellant, e.g., carbon dioxide, nitrogen, propane, etc. with the usual adjuvants such as cosolvents, wetting agents, etc.

Where the pharmaceutical compositions are ointments, the active ingredient can be mixed with a diluent vehicle such as cocoa butter, viscous polyethylene glycols, hydrogenated oils, and such mixtures can be emulsified if desired.

In accordance with the invention, pharmaceutical compositions comprise, as an active ingredient, an effective amount of one or more non-toxic, pharmaceutically acceptable ingredient(s). Examples of such ingredients for use in the compositions include ethanol, dimethyl sulfoxide, glycerol, alumina, starch, calcium carbonate, talc, flour, and equivalent non-toxic carriers and diluents.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

1. A compound which binds to an adenosine receptor, wherein said compound is an epoxide of xanthine, adenosine, or an analog, derivative, isomer, or salt thereof.

2. The compound, according to claim 1, wherein said xanthine epoxide is an epoxide of 1,3-dialkylxanthine.

3. The compound, according to claim 2, wherein said 1,3-dipropylxanthine is selected from the group consisting of 1,3-dipropyl-8-oxiranyl xanthine, 1,3-dipropyl-8-epoxyalkylxanthine; 1,3-dipropyl-8-epoxybicycloalkylxanthine; 1,3-dipropyl-8-{3-oxatricyclo[3.2.1.$0^{2,4}$]oct-6(7)yl} xanthine; and 1,3-dipropyl-8-{7-oxabicyclo[2.2.1]hept-2-en-5(6)yl} xanthine.

4. The compound according to claim 1, wherein said compound has the structure:



wherein R_1 and R_2 are the same or different, and can be H or an alkyl group of 1-4 carbons, and n = 0-4.

5. The compound, according to claim 1, wherein said compound has the structure:



wherein R_1 and R_2 are the same or different, and can be H or an alkyl group of 1-4 carbons, R_3 is either O or $(CH_2)_{1-4}$, and n = 0-4.

6. The compound, according to claim 5, wherein said compound is an *S*-enantiomer having the structure



7. The compound, according to claim 5, wherein said compound is an *R*-enantiomer having the structure



8. The compound, according to claim 1, wherein said adenosine epoxide is an N^6-epoxycycloalkyladenosine.

9. The compound, according to claim 8, wherein said compound has the structure



wherein R =



or



3 wherein R_1 = alkyl of 1-4 carbons.

1 10. A method for modulating the biological activity of adenosine, said method
2 comprising administering an effective amount of a compound, wherein said compound
3 is an epoxide of xanthine, adenosine, or an analog, derivative, isomer, or salt thereof.

1 11. The method, according to claim 10, wherein said compound is a 1,3-
2 dialkylxanthine.

1 12. The method, according to claim 11, wherein said dialkylxanthine is a 1,3-
2 dipropylxanthine selected from the group consisting of 1,3-dipropyl-8-oxiranyl
3 xanthine, 1,3-dipropyl-8-epoxyalkylxanthine; 1,3-dipropyl-8-epoxybicycloalkylxanthine;
4 1,3-dipropyl-8-{3-oxatricyclo[3.2.1.$0^{2,4}$]oct-6(7)yl}xanthine; and 1,3-dipropyl-8-{7-
5 oxabicyclo[2.2.1]hept-2-en-5(6)yl}xanthine.

1 13. The method, according to claim 10, wherein said compound has the
2 structure:



wherein R_1 and R_2 are the same or different, and can be H or an alkyl group of 1-4 carbons, R_3 is either O or $(CH_2)_{1-4}$, and n = 0-4.

14. The method, according to claim 13, wherein said compound is an *S*-enantiomer having the structure



15. The method, according to claim 10, wherein said biological activity of adenosine is modulated for treatment of a patient having a cardiac, renal, hepatic, or pulmonary disease.

16. The method, according to claim 13, wherein the biological activity of adenosine is modulated to produce diuresis.

17. The method, according to claim 13, wherein the biological activity of adenosine is modulated to produce bronchodilation.

18. The method, according to claim 13, wherein, when adenosine is exogenously administered, the biological activity of adenosine is modulated to counteract a side effect of said administered adenosine.

19. The method, according to claim 10, wherein said compound is N^6-epoxycycloalkyladenosine.

20. The method, according to claim 19, wherein said compound has the structure



wherein R =



or



wherein R_1 = alkyl of 1-4 carbons.

21. A composition for modulating biological activity of adenosine, said composition comprising an epoxide of xanthine, adenosine, or an analog, derivative, isomer, or salt thereof, said composition further comprising a pharmaceutically acceptable carrier.

22. The composition, according to claim 21, wherein said xanthine epoxide is an epoxide of 1,3-dialkylxanthine.

23. The composition, according to claim 22, wherein the xanthine epoxide has the structure



wherein R_1 and R_2 are the same or different, and can be H or an alkyl group of 1-4 carbons, R_3 is either O or $(CH_2)_{1-4}$, and n = 0-4.

24. The composition, according to claim 23, wherein said composition is a diuretic.

25. The composition, according to claim 23, wherein said xanthine epoxide is an *S*-enantiomer which has the structure



26. The composition, according to claim 21, wherein said adenosine epoxide comprises an N^6-epoxycycloalkyladenosine.

27. A method for producing an epoxide of xanthine, adenosine or an analog, derivative, isomer, or salt thereof, wherein said method comprises reacting the xanthine, adenosine or analog, derivative, isomer, or salt thereof with dimethyldioxirane.

AUSTRALIAN PATENT OFFICE

28. An epoxide of xanthine, adenosine, or an analog, derivative, isomer or salt thereof, substantially as hereinbefore described with reference to any one of the Examples.

29. A process for the preparation of an epoxide of xanthine, adenosine, or an analog, derivative, isomer or salt thereof, substantially as hereinbefore described with reference to any one of the Examples.

Dated 18 April, 1996
University of Florida Research Foundation, Inc.

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON

AUSTRALIAN PATENT OFFICE


Pr
NH2
H2C=CH(CH2)nCOCl
n= 0-2
NHCO(CH2)nCH=CH2
n= 0-4
(226.28)
1
2
OH-
R
(CH2)n
R= (CH2)1-4 or O
n = 0-4
(CH2)nCH=CH2
n= 0-4
5
3
CO2H
Cl
6
4

Figure 1



Figure 2



Figure 3

4/9

PCT/US94/12388

SUBSTITUTE SHEET (RULE 26)

Figure 4A



Figure 4B





Figure 4C



Figure 4D

Figure 5A



Figure 5B



Figure 5C



Figure 5D




100
80
60
40
20
0
-5
-6
-7
-8
-9
ENX
IBMX
[Drug], Log M
^{3}H-Adenosine Formed, % Control

Figure 6


15
10
5
0
S-H Prolongation (msec)
No ENX
ENX (2 nM)
ENX (2 μM)
Adenosine
MgCl2
Carbachol

Figure 7


15
10
5
0
Vehicle (control)
ENX (S-enantiomer)
ENX (R-enantiomer)
ENX (racemic mixture)
Accumulative Urine Output (ml)
1
2
Hours

Figure 8

INTERNATIONAL SEARCH REPORT

Intern. al Application No
PCT/US 94/12388

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D473/08 C07H19/167 C07D519/00 A61K31/52
//(C07D519/00,493:00,473:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE,A,42 05 306 (GLÜSENKAMP, KARL-HEINZ ET AL) 26 August 1993 *Page 16: example 20* *Page 17: example 7* *Page 19-27: claims* ---	1-3,9, 21-26
A	WO,A,92 00297 (BOEHRINGER INGELHEIM INTERNATIONAL GMBH) 9 January 1992 *Page 65-78: claims* ---	1-3, 21-26
A	EP,A,0 415 456 (KYOWA HAKKO KOGYO CO.,LTD.) 6 March 1991 *Page 1-4* ---	1-3, 21-26
A	EP,A,0 374 808 (BOEHRINGER INGELHEIM KG) 27 June 1990 *Page 1-5* --- -/--	1-3, 21-26

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 February 1995	20. 02. 95

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Luyten, H

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Intern. ial Applicaton No
PCT/US 94/12388

C.(Conunuaton) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citaton of document, with indicaton, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,94 16702 (KYOWA HAKKO KOGYO CO., LTD.) 4 August 1994 *Page 0*	1-3, 21-26
P,A	US,A,5 288 721 (J.PETER KLEIN ET AL) 22 February 1994 *Document*	1-3, 21-26

Form PCT/ISA/210 (continuaton of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 94/ 12388

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 10-20 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searches without effort justifying an additional fee, this Authority did not inv of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern ıal Application No
PCT/US 94/12388

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE-A-4205306	26-08-93	NONE		
WO-A-9200297	09-01-92	DE-A-	4019892	02-01-92
		CA-A-	2064742	23-12-91
		EP-A-	0487673	03-06-92
		JP-T-	5501265	11-03-93
EP-A-0415456	06-03-91	CA-A-	2024381	02-03-91
		JP-A-	3173889	29-07-91
		JP-B-	6102662	14-12-94
		US-A-	5290782	01-03-94
EP-A-0374808	27-06-90	DE-A-	3843117	28-06-90
		AU-B-	637990	17-06-93
		AU-A-	4707289	28-06-90
		CA-A-	2006387	22-06-90
		DE-U-	8817122	04-02-93
		NO-C-	173502	22-12-93
		NZ-A-	231901	23-12-93
		PL-B-	162877	31-01-94
		US-A-	5175291	29-12-92
WO-A-9416702	04-08-94	NONE		
US-A-5288721	22-02-94	AU-B-	5138493	12-04-94
		WO-A-	9406431	31-03-94